A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media

EMBO Molecular Medicine

Volumn 6, Issue 1, 2014, Pages 141-154

  Rosch, Jason W ^a   Iverson, Amy R ^a   Humann, Jessica ^a   Mann, Beth ^a   Gao, Geli ^a   Vogel, Peter ^a   Mina, Michael ^b   Murrah, Kyle A ^c   Perez, Antonia C ^c   Edward Swords, W ^c   Tuomanen, Elaine I ^a   Mccullers, Jonathan A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Otitis media; Streptococcus; Vaccine; Virulence

Indexed keywords

IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; LIVE VACCINE; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; INFLUENZA VIRUS; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; SEROTYPE; SINUSITIS; VACCINATION; VIRULENCE; VIRUS STRAIN;

ACUTE DISEASE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHINCHILLA; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; SEROTYPING; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; VACCINES, ATTENUATED; VIRULENCE FACTORS;

EID: 84891950263     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201202150     Document Type: Article

References (47)

1. Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW, Mitchell TJ, Hansman D, Paton JC (1994) Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62: 5683-5688
2. Arora S, McDonald RA, Toews GB, Huffnagle GB (2006) Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice. Infect Immun 74: 4339-4348
3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187-195
4. Chimalapati S, Cohen J, Camberlein E, Durmort C, Baxendale H, de Vogel C, van Belkum A, Brown JS (2011) Infection with conditionally virulent Streptococcus pneumoniae Deltapab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains. Infect Immun 79: 4965-4976
5. Coco A, Vernacchio L, Horst M, Anderson A (2010) Management of acute otitis media after publication of the 2004 AAP and AAFP clinical practice guideline. Pediatrics 125: 214-220
6. Cohen JM, Chimalapati S, de Vogel C, van Belkum A, Baxendale HE, Brown JS (2012) Contributions of capsule, lipoproteins and duration of colonisation towards the protective immunity of prior Streptococcus pneumoniae nasopharyngeal colonisation. Vaccine 30: 4453-4459
7. Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, Takata GS (2010) Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: A systematic review. JAMA 304: 2161-2169
8. Crowley PJ, Svensater G, Snoep JL, Bleiweis AS, Brady LJ (2004) An ffh mutant of Streptococcus mutans is viable and able to physiologically adapt to low pH in continuous culture. FEMS Microbiol Lett 234: 315-324
9. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, et al (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: Randomised, double-blind, placebo-controlled trial. Lancet 365: 1139-1146
10. Daeron M (1997) Fc receptor biology. Annu Rev Immunol 15: 203-234
11. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, et al (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344: 403-409
12. Francis KP, Yu J, Bellinger-Kawahara C, Joh D, Hawkinson MJ, Xiao G, Purchio TF, Caparon MG, Lipsitch M, Contag PR (2001) Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect Immun 69: 3350-3358
13. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, Griffin MR (2006) National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118: 865-873
14. Horton RM (1995) PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Mol Biotechnol 3: 93-99
15. Kazanjian P (2004) Changing interest among physicians toward pneumococcal vaccination throughout the twentieth century. J Hist Med Allied Sci 59: 555-587
16. Kim EH, Choi SY, Kwon MK, Tran TD, Park SS, Lee KJ, Bae SM, Briles DE, Rhee DK (2012) Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine 30: 2008-2019
17. Knuf M, Kowalzik F, Kieninger D (2011) Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 29: 4881-4890
18. Lizcano A, Chin T, Sauer K, Tuomanen EI, Orihuela CJ (2010) Early biofilm formation on microtiter plates is not correlated with the invasive disease potential of Streptococcus pneumoniae. Microbial pathogenesis 48: 124-130
19. Lottenbach KR, Mink CM, Barenkamp SJ, Anderson EL, Homan SM, Powers DC (1999) Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 67: 4935-4938
20. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M (2005) CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102: 4848-4853
21. Mangtani P, Cutts F, Hall AJ (2003) Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 3: 71-78
22. Mann B, van Opijnen T, Wang J, Obert C, Wang YD, Carter R, McGoldrick DJ, Ridout G, Camilli A, Tuomanen EI, et al (2012) Control of virulence by small RNAs in Streptococcus pneumoniae. PLoS Pathog 8: e1002788.
23. McAuley JL, Hornung F, Boyd KL, Smith AM, McKeon R, Bennink J, Yewdell JW, McCullers JA (2007) Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2: 240-249
24. McCool TL, Cate TR, Tuomanen EI, Adrian P, Mitchell TJ, Weiser JN (2003) Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun 71: 5724-5732
25. McCullers JA (2004) Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 190: 519-526
26. McCullers JA (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19: 571-582
27. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA (2007) Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 3: e28.
28. McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B (2010) Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 202: 1287-1295
29. McCullers JA, Rehg JE (2002) Lethal synergism between influenza virus and Streptococcus pneumoniae: Characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186: 341-350
30. Melin MM, Hollingshead SK, Briles DE, Lahdenkari MI, Kilpi TM, Kayhty HM (2008) Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae. Clin Vaccine Immunol 15: 1529-1535
31. Neef J, Andisi VF, Kim KS, Kuipers OP, Bijlsma JJ (2011) Deletion of a cation transporter promotes lysis in Streptococcus pneumoniae. Infect Immun 79: 2314-2323
32. Nunes MC, Madhi SA (2011) Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines 10: 951-980
33. Rapola S, Jantti V, Haikala R, Syrjanen R, Carlone GM, Sampson JS, Briles DE, Paton JC, Takala AK, Kilpi TM, et al (2000) Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 182: 1146-1152
34. Riberdy JM, Flynn KJ, Stech J, Webster RG, Altman JD, Doherty PC (1999) Protection against a lethal avian influenza A virus in a mammalian system. J Virol 73: 1453-1459
35. Roche AM, King SJ, Weiser JN (2007) Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 75: 2469-2475
36. Rodgers GL, Arguedas A, Cohen R, Dagan R (2009) Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: Potential implications for pneumococcal conjugate vaccines. Vaccine 27: 3802-3810
37. Rosch JW, Sublett J, Gao G, Wang YD, Tuomanen EI (2008a) Calcium efflux is essential for bacterial survival in the eukaryotic host. Mol Microbiol 70: 435-444
38. Rosch JW, Vega LA, Beyer JM, Lin A, Caparon MG (2008b) The signal recognition particle pathway is required for virulence in Streptococcus pyogenes. Infect Immun 76: 2612-2619
39. Shapiro DJ, Gonzales R, Cabana MD, Hersh AL (2011) National trends in visit rates and antibiotic prescribing for children with acute sinusitis. Pediatrics 127: 28-34
40. Sharma SK, Casey JR, Pichichero ME (2011) Reduced memory CD4+ T-cell generation in the circulation of young children may contribute to the otitis-prone condition. J Infect Dis 204: 645-653
41. Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI (2011) Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US. Vaccine 29: 8042-8048
42. Simell B, Korkeila M, Pursiainen H, Kilpi TM, Kayhty H (2001) Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children. J Infect Dis 183: 887-896
43. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA (2007) Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 57: 82-89
44. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M (2012) Impact of pneumococcal conjugate vaccination on otitis media: A systematic review. Clin Infect Dis 54: 1765-1773
45. Trevino J, Perez N, Sumby P (2010) The 4.5S RNA component of the signal recognition particle is required for group A Streptococcus virulence. Microbiology 156: 1342-1350
46. Wanzeck K, Boyd KL, McCullers JA (2011) Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care Med 183: 767-773
47. Zhang Z, Clarke TB, Weiser JN (2009) Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119: 1899-1909